Hyperscale Data (GPUS) shares rallied after the company said Monday that preliminary Q1 revenue exceeded $25 million.
Shares soared over 400% as intraday trading volume grew to over 253 million from a daily average of about 90,000.
Immutep (IMMP) said Monday that a phase 2b trial evaluating eftilagimod alfa in combination with Merck's (MRK) Keytruda as first line therapy in head and neck cancer patients produced an "excellent" median overall survival result of 17.6 months.
Shares soared 38% as intraday trading volume surged to over 5.51 million from a daily average of roughly 72,000.
BioCryst Pharmaceuticals (BCRX) shares jumped 15% following better-than-expected Q1 results.
Trading volume was more than 16 million, against a daily average of about 3.69 million.
Price: 7.15, Change: +5.78, Percent Change: +421.90
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.